Drug Trial Radar · NCT01384734
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Last checked: Nov 19, 2026Latest source record: Nov 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
254
Actual
Start
Jul 26, 2011
Primary completion
Feb 18, 2013
Study completion May 12, 2017
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 29, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, efficacy, tolerability and pharmacokinetics of four doses of BMS-663068 with Raltegravir (RAL) + Tenofovir Disoproxil Fumarate (TDF). At least 1 dose of BMS-663068 can be identified which is safe, well tolerated, and efficacious when combined with RAL + TDF for treatment-experienced HIV-1 infected subjects. PHENOSENSE® is a registered trademark of Monogram Biosciences.
Conditions
- Infection, Human Immunodeficiency Virus
Interventions
BMS-663068 400 mgDrug
Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
BMS-663068 800 mgDrug
Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
BMS-663068 600 mgDrug
Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
BMS-663068 1200 mgDrug
Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Raltegravir 400 mgDrug
Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Tenofovir 300 mgDrug
Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Ritonavir 100 mgDrug
Tablets, Oral, 100 mg, Once daily, 96 weeks
Atazanavir 300 mgDrug
Capsules, Oral, 300 mg, Once daily, 96 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) < 50 Copies Per Milliliter (c/mL) at Week 24Time frame: Week 24
- Number of Participants With Serious Adverse Events (SAE) and Discontinuation Due to AEs up to Week 24Time frame: Up to Week 24
Locations
54 sites in 10 countries. Site status is shown where the registry gives one.
GSK Investigational Site
San Francisco, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Coral Gables, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
New York, New York
GSK Investigational Site
Durham, North Carolina
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Austin, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Longview, Texas
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Córdoba, Argentina
GSK Investigational Site
Rosario, Argentina
GSK Investigational Site
Ciudad de Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
Rosario, Santa Fe Province, Argentina
GSK Investigational Site
Bogotá, Colombia
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Hamburg, Germany
GSK Investigational Site
München, Germany
GSK Investigational Site
Bonn, North Rhine-Westphalia, Germany
GSK Investigational Site
Aguascalientes, Mexico
GSK Investigational Site
DF, Mexico
GSK Investigational Site
Distrito Federal, Mexico
GSK Investigational Site
Mexico City, Mexico
GSK Investigational Site
Guadalajara, Jalisco, Mexico
GSK Investigational Site
Zapopan, Jalisco, Mexico
GSK Investigational Site
San Luis Potosí City, San Luis Potosí, Mexico
GSK Investigational Site
Lima, Peru
GSK Investigational Site
Lima, Peru
GSK Investigational Site
Lima, Peru
GSK Investigational Site
Lima, Peru
GSK Investigational Site
Lima, Peru
GSK Investigational Site
Lima, Peru
GSK Investigational Site
Iquitos, Loreto, Peru
GSK Investigational Site
Bucharest, Romania
GSK Investigational Site
Constanța, Romania
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.